WASHINGTON — House lawmakers on both sides of the aisle Wednesday stressed the importance of developing new antibiotics, though the draft bill they discussed did not include any of the specific incentives advocates say are necessary to promote such drug development.

Left to their own devices and the stimuli of the market, companies simply won’t develop the antibiotics the world needs. Infections resistant to the current supply of medicines kill tens of thousands of Americans each year, and many more worldwide. But these drugs can’t turn a huge profit, and the more they are used, the less effective they can become, making it difficult for companies to recoup their investment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy